

Vétoquinol

a Sign of Passion

FORCYL® EUROPEAN LAUNCH OF NEW DRUG

Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection.



The Vétoquinol Group, a marbofloxacin world expert, is the first veterinary pharmaceutical laboratory to have developed the use of this molecule for cattle, pigs and pets.

Vétoquinol has been able to bring to market this new single-injection treatment procedure thanks to its scientific expertise in the fields of pharmacology and pharmacodynamics coupled with extensive R&D work. This treatment complies with the latest official requirements concerning the use of antibiotics in animal health, and the single injection procedure (SISAAB* concept) greatly simplifies the administering of the drug. Vétoquinol's ability to capitalize on its know-how has enabled it to register an international patent for Forcyl®, and obtain marketing authorizations in most European countries.

"With Forcyl®, Vétoquinol can now offer a new, innovative, patented product for cattle", Vétoquinol CEO Matthieu Frechin explained. "This new drug will bolster our anti-infectives range and should help us to increase our market share in this competitive sector. This is the target that we have set for our sales, marketing and technical teams for the upcoming months and years."

*SISAAB: The SISAAB concept (**S**ingle **I**njection **S**hort **A**cting **A**nti**B**iotic) has been developed as a method of treatment for acute respiratory diseases in cattle. It consists of a single injection of a strong dose of antibiotic, allowing a high concentration of active substance to be reached in a short space of time; it minimizes the danger of resistance thanks to a rapid elimination of the active ingredient.

About Vétoquinol

Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group, dedicated exclusively to animal health, is the 10th largest animal healthcare laboratory in the world. More than 80% of its revenues are generated outside France.

Vétoquinol's business includes research and development, production and marketing of medicinal and non-medicinal products. Vétoquinol has positioned itself in the curative sector and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation and cardiology/nephrology.

The Group currently distributes its products in more than one hundred countries throughout Europe, North America and Asia/Pacific, with subsidiaries in 24 countries and a network of 140 distribution partners. The company has more than 1,700 employees worldwide.

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For more information, contact:

VETOQUINOL

Investor Relations

Marie-Josée AUBRY-ROTA

Tel.: +33 3 84 62 59 88

relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor Relations

Emmanuel DOVERGNE

Tel.: +33 1 56 43 44 63

emmanuel.dovergne@keima.fr

Media Relations

Alix HÉRIARD DUBREUIL

Tel.: +33 1 56 43 44 62

alix.heriard@keima.fr